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Women with urinary tract infections (UTIs) in Califor-
nia, USA (1999–2001), were infected with closely related or 
indistinguishable strains of Escherichia coli (clonal groups), 
which suggests point source dissemination. We compared 
strains of UTI-causing E. coli in California with strains caus-
ing such infections in Montréal, Québec, Canada. Urine 
specimens from women with community-acquired UTIs 
in Montréal (2006) were cultured for E. coli. Isolates that 
caused 256 consecutive episodes of UTI were character-
ized by antimicrobial drug susceptibility proﬁ  le, enterobac-
terial repetitive intergenic consensus 2 PCR, serotyping, 
XbaI and NotI pulsed-ﬁ  eld gel electrophoresis, multilocus 
sequence typing, and phylogenetic typing. We conﬁ  rmed 
the presence of drug-resistant, genetically related, and tem-
porally clustered E. coli clonal groups that caused commu-
nity-acquired UTIs in unrelated women in 2 locations and 2 
different times. Two clonal groups were identiﬁ  ed in both lo-
cations. Epidemic transmission followed by endemic trans-
mission of UTI-causing clonal groups may explain these 
clusters of UTI cases.
C
ommunity-acquired extraintestinal infections with Es-
cherichia coli range in frequency from 6 to 8 million 
cases of uncomplicated cystitis per year to 127,500 cases of 
sepsis per year in the United States (1). Urinary tract infec-
tions (UTIs) caused by E. coli are one of the most common 
extraintestinal infections in women and, because of their 
high incidence, are the focus of most epidemiologic stud-
ies. The source of E. coli for these infections is a person’s 
intestinal tract; however, how these E. coli are acquired by 
the gut is unclear. Risk factors that lead to intestinal colo-
nization with extraintestinal E. coli differ from factors as-
sociated with development of infection.
Young, otherwise healthy, sexually active women 
have the highest risk for community-acquired UTIs. The 
main risk factors for UTI are recent and frequent sexual 
intercourse, contraceptive use, and a history of UTIs (2,3). 
Treatment for UTIs usually involves a short course of an 
antimicrobial drug, such as trimethoprim-sulfamethoxazole 
(TMP-SMZ). Over the past decade, the prevalence of drug 
resistance in E. coli has increased dramatically, compli-
cating management of these infections. Across the United 
States and Canada, urinary tract isolates of E. coli from out-
patient clinics showed increased resistance to TMP-SMZ 
and ampicillin (4). A more serious concern has been the 
gradual increase in ﬂ  uoroquinolone (e.g., ciproﬂ  oxacin) re-
sistance among UTI isolates (5).
There is increasing evidence that the E. coli that cause 
UTIs and other extraintestinal infections may be responsi-
ble for community-wide epidemics. In 1986–1987, E. coli 
O15:K52:H1 caused an outbreak of community-acquired 
UTIs and septicemia in South London, England (6). The 
distinctive drug resistance proﬁ  le of this clonal group con-
tributed to its recognition in London and other areas of Eu-
rope and the United States (7,8). Other outbreaks of UTI 
caused by E. coli have been described and include a cluster 
of UTI cases in Copenhagen, Denmark, caused by E. coli 
O78:H10 and a larger outbreak in Calgary, Alberta, Can-
ada, caused by extended-spectrum β-lactamase (ESBL)–
producing E. coli (9,10).
In 2001, we reported that a multidrug-resistant E. coli 
clonal group designated clonal group A (CgA), deﬁ  ned 
by an enterobacterial repetitive intergenic consensus 2 
(ERIC2) PCR and characterized by O11, O77, O17, and 
O73:K52:H18 serotypes, caused 11% of all E. coli UTIs 
and 49% of all TMP-SMZ–resistant E.  coli UTIs in 1 
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California, USA, community over a 4-month period (11). 
Members of this clonal group were responsible for drug-
resistant UTIs in university communities in Michigan and 
Minnesota and a community in Colorado (12), and for 
pyelonephritis in several states (13). We also identiﬁ  ed ad-
ditional clonal groups in a second cross-sectional study in 
Berkeley, California (14).
Identiﬁ  cation of outbreak strains of E. coli that cause 
extraintestinal infections suggests that point sources, possi-
bly contaminated food, may be responsible for local spread 
of genetically related E. coli strains in the United Kingdom. 
Recent work in the United Kingdom has focused on a pos-
sible link between the increase in ESBL-producing E. coli 
and food animal production. An estimated 30,000 cases 
of human infection with ESBL-producing E.  coli occur 
each year in the United Kingdom, and studies have found 
epidemic strains of ESBL-producing E. coli in the United 
Kingdom and throughout the world (15–17). The Health 
Protection Agency has suggested that imported chicken 
may be a route for introduction of ESBL-producing E. coli 
into the United Kingdom. Recent research by this agency 
did not identify a direct link between ESBL-positive strains 
of E. coli and chickens and humans (18), but other inves-
tigators found evidence for a link between drug resistance 
and speciﬁ  c genotypes of extratintestinal E. coli in animal 
food products and human infections in Minnesota and 
Washington, DC (19–21).
To further investigate the molecular epidemiology of 
disseminated E. coli clonal groups that cause UTIs, we con-
ducted a cross-sectional study in a population of university 
women from Montréal, Québec, Canada, with UTI caused 
by E. coli and compared these organisms with those iso-
lated from women with UTI in California. We sought to 
identify women in similar risk groups, but at different times 
and in different locations, to determine whether unrelated 
women with UTIs caused by indistinguishable strains of E. 
coli could be identiﬁ  ed, and to determine whether the dis-
tribution was identical of clonal groups that were causing 
UTIs in these 2 communities.
Methods
Study Design
We conducted a cross-sectional study in collaboration 
with the Student Health Services at McGill University in 
Montréal in 2006. Eligible women 18–45 years of age who 
came to the health center with a suspected UTI were enrolled 
in the study. A UTI was clinically deﬁ  ned as >2 symptoms 
suggestive of this infection and included dysuria, increased 
urinary frequency or urgency, pyuria, hematuria, and >102 
CFUs of E. coli/mL of clean-catch urine. If a woman had 
>1 UTIs during the study period, only data concerning the 
ﬁ  rst UTI was eligible for inclusion in the analyses. Details 
of studies in California have been reported (11,14). The 
study protocol was reviewed and approved by the McGill 
University, Institutional Review Board (A01-M04–05A).
Isolation of E. coli
Urine samples were immediately cultured on Uricult 
(Orion Diagnostica, Espoo, Finland) MacConkey/cysteine 
lactose electrolyte–deﬁ  cient agar dip slides. One arbitrarily 
selected colony (or multiple if morphologically different 
colonies were present) was selected from the MacCon-
key side. Lactose- and indole-positive colonies were pre-
sumptively identiﬁ  ed as E. coli (22). Those isolates that 
were either lactose or indole negative were cultured on 
CHROMagar orientation plates (Becton Dickinson BBL 
Diagnostics, Sparks, MD, USA) and tested for lysine and 
ornithine decarboxylases (Moeller decarboxylase tests; 
PML Microbiologicals, Mississauga, Ontario, Canada). 
The reference strains used for carboxylase testing included 
Klebsiella pneumoniae (American Type Culture Collection 
[ATCC] no. 13883) and Enterobacter cloacae (ATCC no. 
13047). Those isolates that were classiﬁ  ed as E. coli on the 
CHROMagar plates and positive for lysine and ornithine 
decarboxylases were presumptively identiﬁ  ed as E. coli. 
One E. coli isolate from each urine culture was arbitrarily 
selected for further analysis.
Antimicrobial Drug Susceptibility
Isolates were screened for susceptibility to TMP-
SMZ, ciproﬂ  oxacin, cephalothin, nitrofurantoin, ampicillin, 
chloramphenicol, streptomycin, and tetracycline by the disk 
diffusion assay (Becton Dickinson BBL Diagnostics). E. coli 
strain ATCC 25922 was used as the reference strain. Iso-
lates were deﬁ  ned as resistant, intermediate, or susceptible 
to each antimicrobial drug according to Clinical and Labo-
ratory Standards Institute interpretive criteria (23). Isolates 
with intermediate resistance were deﬁ  ned as susceptible.
ERIC2 PCR Fingerprinting
All E. coli isolates were screened by using the ERIC2 
PCR ﬁ  ngerprinting assay (24). Images of electrophoretic 
patterns were scanned into a software program (GelCom-
par II version 3.5; Applied Maths Inc., Austin, TX, USA) 
for analysis. Dendrograms based on ERIC2 PCR patterns 
were inferred from the Dice similarity coefﬁ  cient matrix 
generated by GelCompar by the unweighted pair group 
method with arithmetic averages. Isolates with ﬁ  nger-
prints that were indistinguishable on visual inspection or 
by GelCompar II version 3.5 (Applied Maths Inc.) analysis 
were grouped and selected for further typing.
Pulsed-Field Gel Electrophoresis
XbaI and NotI pulsed-ﬁ  eld gel electrophoresis (PFGE) 
was conducted on all putative clonal isolates, as deﬁ  ned 
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by ERIC2 PCR (25). Isolates showing <6 band differenc-
es in their patterns were considered to be possibly related 
according to the criteria of Tenover et al. (26). Images of 
patterns were scanned into GelCompar II version 3.5 and 
analyzed as for ERIC2 PCR.
Serotypes
Serotyping was performed for Montréal E. coli isolates 
that were indistinguishable by ERIC2 PCR. O and H sero-
typing was performed by the Enteric Diseases Program at the 
National Microbiology Laboratory, Winnipeg, Manitoba, 
Canada, by using established protocols. Isolates from Cali-
fornia were evaluated for serogroup only at the E. coli Refer-
ence Center (Pennsylvania State University, University Park, 
PA, USA). Isolates that were motile but non reactive with O 
or H antiserum were classiﬁ  ed as nontypeable (OUNTYPE) 
and those that were nonmotile were denoted (HNM).
Multilocus Sequence Typing and 
Determination of Phylogenetic Group
Multilocus sequence typing (MLST) was performed 
as described (27). Gene ampliﬁ  cation and sequencing were 
performed by using the primers speciﬁ  ed at the E.  coli 
MLST website (http://web.mpiib-berlin.mpg.de/mlst/dbs/
Ecoli). Allelic proﬁ  le and sequence type (ST) determina-
tions were assigned according to the E. coli MLST website 
scheme. The major E. coli phylogenetic group (A, B1, B2, 
and D) was determined by using a multiplex PCR (28).
Clonal Group
A clonal group was deﬁ  ned as >2 E. coli isolates show-
ing indistinguishable patterns by ERIC2 PCR. These groups 
were given letter designations, such as CgA. Clonal group 
designations assigned for the California study isolates 
were retained (CgA to CgG), and clonal groups identiﬁ  ed 
in Montréal were assigned new letter designation begin-
ning with CgH. To support categorization of these clonal 
groups, isolates showing indistinguishable ERIC2 PCR 
patterns were also evaluated by PFGE, serotyping, drug 
susceptibility testing, MLST, and phylogenetic typing.
Statistical Analyses
All analyses were conducted by using Stata version 9.0 
(Stata Corporation, College Station, TX, USA). Proportions 
and 95% conﬁ  dence intervals (CIs) were estimated. Differ-
ences in proportions were assessed by χ2 tests. Statistical 
signiﬁ  cance was deﬁ  ned by p<0.05.
Results
Study Participants
From January 2006 to January 2007, 656 urine samples 
were submitted. E. coli was isolated from 300 urine sam-
ples obtained from 256 women in Montréal. Only samples 
from the ﬁ  rst UTI were included in the analyses. A total of 
311 (47%) samples yielded no bacteria, and 45 (7%) con-
tained an organism other than E. coli. Results for the E. coli 
isolated from these 256 women with UTIs were compared 
with results for E. coli isolated from 434 women with UTIs 
in California (1999–2001).
Antimicrobial Drug Susceptibility
Antimicrobial drug resistance for the Montréal and Cali-
fornia isolates is summarized in Table 1. For the drugs tested, 
isolates from Montréal showed comparable resistance levels 
to those from California, although resistance to TMP-SMZ 
was higher in isolates from California (20% in California vs. 
14% in Montréal; p = 0.07) and ciproﬂ  oxacin resistance was 
slightly higher in isolates from Montréal (2% in California 
vs. 4% in Montréal; p = 0.06). Resistance to nitrofurantoin 
was not detected in isolates from either location.
ERIC2 PCR Fingerprinting
ERIC2 PCR ﬁ  ngerprinting identiﬁ  ed 4 clonal groups 
(CgA, CgC, CgH, and CgI) among Montréal isolates (data 
not shown). The prevalence of these clonal groups in Mon-
tréal in 2006 was 13 CgA (5%, 95% CI 0.03–0.09), 10 CgC 
(4%, 95% CI 0.02–0.07), 7 CgI (3%, 95% CI 0.01–0.06), 
and 5 CgH (2%, 95% CI 0.01–0.04). CgA and CgC were 
identiﬁ  ed from both study sites. In the California studies, 32 
CgA isolates (7%, 95% CI 0.05–0.10) and 12 CgC isolates 
(3%, 95% CI 0.01–0.05) were identiﬁ  ed. Clonal groupings 
were conﬁ  rmed by PCR reampliﬁ  cation, and these group-
ings also included representatives of clonal groups identi-
ﬁ  ed in the California studies (11,14).
CgH was uniformly resistant to ampicillin and strep-
tomycin and susceptible to all other drugs tested. CgC was 
susceptible to all drugs tested (except for 1 isolate that was 
resistant to ampicillin). CgA was primarily resistant to TMP-
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Table 1. Antimicrobial drug resistance of Escherichia coli*   
Characteristic 
Berkeley, 
California, 
USA† 
Montréal, 
Québec, 
Canada‡  p value§ 
Total primary E. coli 434 256   
Drug   No. (%) resistant   
 Trimethoprim- 
 sulfamethoxazole 
85 (20)  36 (14)  0.07 
  Cephalothin  11 (3)  7 (3)  0.90 
  Ciprofloxacin  8 (2)  11 (4)  0.06 
 Nitrofurantoin  0  0   
 Ampicillin  ND  83  (32)  ND 
 Tetracycline  ND  40  (16)  ND 
 Chloramphenicol  ND  7  (3)  ND 
 Streptomycin  ND  48  (19)  ND 
*ND, not done. 
†October 1999–January 2000 and October 2000– January 2001. 
‡January 2006–January 2007 
§By Ȥ
2 test. RESEARCH
SMZ and ampicillin; resistance to the other drugs varied. 
CgI showed the most extensive resistance. This group was 
resistant to ciproﬂ  oxacin and TMP-SMZ, and 2 members of 
CgI were resistant to 5 drugs. Drug-resistance proﬁ  les for 
each clonal group member from both study sites are shown 
in Table 2 and the online Appendix Table (available from 
www.cdc.gov/EID/content/14/10/1575-appT.htm).
Pulsed-Field Gel Electrophoresis
PFGE conﬁ   rmed the presence of 4 clonal groups 
among the Montréal isolates. CgH was found only in Mon-
tréal and showed indistinguishable XbaI and NotI PFGE 
patterns (Figure 1). CgI was also found only in Montréal 
and could be considered possibly related by the criteria 
of Tenover et al. (26) (Figure 2). Patterns of CgC isolates 
(Figure 3) identiﬁ  ed in California and Montréal differed by 
<6 bands, regardless of restriction enzyme used. The PFGE 
results for CgA varied the most among all clonal groups 
from Montréal; in some cases, the PFGE patterns showed 
>6 band differences (Figure 4).
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Table 2. Characteristics of clonal isolates of Escherichia coli from women with urinary tract infections, Montréal, Québec, Canada, 
2006
Antimicrobial drug resistance profile§ 
Isolate
no. Genotype* Serotype MLST† Phy‡  Date  of  infection CIP CEP NIT
TMP-
SMZ AMP CAM STR TET
362 C O1:H7 ST95 B2 2006 Jan 23  0 0 0 0 0 0 0 0
363 C O1:H7 2006 Jan 23  0 0 0 0 0 0 0 0
4 1 3 C O 1 8 : H 7S T 9 5 B 2 2 0 0 6  F e b  1 3   00000000
4 1 4 C O 1 : H 7 2 0 0 6  F e b  1 3   00000000
4 3 9 C O 1 : H 7 2 0 0 6  F e b  2 8   00000000
762 C O1:K1:H7 ST95 B2 2006 Sep 28  0 0 0 0 0 0 0 0
767 C O1:K1:H7 2006 Sep 29  0 0 0 0 1 0 0 0
782 C O2:K1:H7 ST95 B2 2006 Oct 10  0 0 0 0 0 0 0 0
957 C O1:H7 2007 Jan 1  0 0 0 0 0 0 0 0
958 C O1:H7 ST95 B2 2007 Jan 5  0 0 0 0 0 0 0 0
412 H O6:H1 ST73 B2 2006 Feb 13  0 0 001010
415 H O6:H1 2006 Feb 13  00001010
4 2 2 H O 6 : H 1 2 0 0 6  F e b  1 6   00001010
4 5 9 H O 6 : H 1 2 0 0 6  M a r  1 0   00001010
4 7 1 H O 6 : H 1 2 0 0 6  M a r  1 6   00001010
385 A OR:H18  ST69 D 2006 Jan 30  0 0 0 0 1 0 1 0
434 A O73:H18 ST69 D 2006  Feb  27  00000000
498 A O77/17:H18  ST69 D 2006 Mar 24  00011010
713 A OUNTYPE: 
HNM
ST69 D 2006 Sep 11  0 0 0 1 1 0 1 0
724 A O15:H18  ST69 D 2006 Sep 13  0 0 0 0 0 0 0 0
799 A OUNTYPE: 
H18
ST69 D 2006 Oct 16  0 0 0 1 1 0 1 0
839 A O17:H18  ST69 D 2006 Nov 2  0 0 0 1 0 0 0 0
860 A O25:H18  ST69 D 2006 Nov 11  0 0 0 0 0 1 0 1
868 A OUNTYPE: 
H18
ST69 D 2006 Nov 15  0 0 0 0 0 0 0 0
9 0 8 A O 1 7 : H 1 8   S T 6 9 D2 0 0 6  N o v  3 0   00011001
9 1 2 A O 1 7 : H 1 8   S T 6 9 D2 0 0 6  N o v  3 0   00011010
913 A O17:HNM  ST69 D 2006 Dec 1  0 0 000001
956 A OUNTYPE: 
H18
ST69 D 2007 Jan 3  0 0 0 0 0 1 1 1
375 I O25:H4 ST131 B2 2006 Jan 25  1 0 0 0 1 0 0 0
4 5 2 I O 2 5 : H 4 S T 1 3 1 B 22 0 0 6  M a r  8   10011001
544 I O25:H4 2006 Apr 19  1 0000000
550 I O25:HNM  ST131 B2 2006 Apr 20  1 0 0 1 1 0 1 1
760 I O25:H4 2006 Sep 28  1 0 0 1 1 0 0 1
7 8 3 I O 2 5 : H 4 2 0 0 6  O c t  1 1   10001000
841 I O25:H4 ST131 B2 2006 Nov 3  1 0 0 1 1 0 1 1
*Determined by ERIC2 PCR (24).
†MLST, multilocus sequence typing, according to Tartof et al. (27); ST, sequence type. 
‡Phy, phylogenetic group, determined by multiplex PCR (28).
§0, sensitive; 1, resistant, according to Clinical and Laboratory Standards Institute interpretative criteria (23). CIP, ciprofloxacin; CEP, cephalothin; NIT, 
nitrofurantoin; TMP-SMZ, trimethoprim-sulfamethoxazole; AMP, ampicillin; CAM, chloramphenicol; STR, streptomycin; TET, tetracycline. UTI-causing Escherichia coli
Serotypes
Serotype results for all clonal E. coli isolates identi-
ﬁ  ed in California and Montréal are shown in Table 2 and 
the Appendix Table. Serotyping was consistent within each 
clonal group, except for CgA, which showed 6 serogroups 
(O11, O77, O17, O73, O25, and O15) although O25 and 
O15 occurred only once. The complete serotype for CgA 
was O11/O17/O77/O73:K52:H18. CgC from both study 
locations showed the same serotype (O1/O18/O2:K1:H7).
MLST
Sequence types for selected members of each clonal 
group from the California and Montréal studies were deter-
mined (Table 2; Appendix Table). All sequence types were 
internally consistent within the clonal group. CgC and CgA 
isolates from both study sites showed the same sequence 
types (ST95 and ST69, respectively). CgH, CgB, and CgD 
showed the same sequence type (ST73). These 3 clonal 
groups also showed similar serogroups and phylogenetic 
groups but showed variable ERIC2 PCR and PFGE patterns; 
thus, they were not placed in the same clonal grouping.
Phylogenetic Group
Phylogenetic group was determined for selected mem-
bers of each clonal group (Table 2 and Appendix Table). 
All phylogenetic group assignments were internally con-
sistent within the clonal group and classiﬁ  ed as either phy-
logenetic group B2 or D; both are typically associated with 
extraintestinal E. coli.
Time Cluster Analyses
In considering the hypothesis of endemic versus epi-
demic transmission of these clonal groups, temporal clus-
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Figure 1. XbaI and NotI pulsed-ﬁ  eld gel electrophoresis patterns for 
clonal group H Escherichia coli isolated from women with urinary tract 
infections in Montréal, Québec, Canada, 2006. The 5 isolates shown 
were serogroup O6:H1. First and last lanes, bacteriophage λ.
Figure 2. XbaI and NotI pulsed-ﬁ  eld gel electrophoresis patterns 
for clonal group I Escherichia coli isolated from women with urinary 
tract infections in Montréal, Québec, Canada, 2006. The 6 isolates 
shown were resistant to ciproﬂ  oxacin and in serogroup O25:H4. 
First and last lanes, bacteriophage λ; lane +, positive control. 
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tering is a useful factor. Figure 5 shows the temporal pat-
tern by week of UTI cases for all clonal groups in Montréal 
(Figure 5, panel A) and in California (Figure 5, panel B). 
Fluctuation in the number of E. coli UTIs over time cor-
responds closely to observation of clonal group–associated 
UTI cases. These results show clustering of some clonal 
groups, e.g., 3 of the 5 UTIs caused by CgH occurred in 
Montréal during week 7, and CgH did not appear again in 
Montréal after week 11. In California, CgA was present 
more frequently between October 1999 and February 2000 
and dropped by 39% between the 2 sampling periods (14). 
CgB and CgD occurred exclusively in the second phase of 
the California study (Figure 5, panel B). Other clonal groups 
appeared throughout the year, although they often clustered 
by week. CgC was present during both data collection peri-
ods in California and caused UTIs throughout 2006 in Mon-
tréal. No clonal group members were identiﬁ  ed during the 
summer in Montréal. However, this period corresponded to 
a decrease in the number of UTI cases at the student health 
services because of lower summer university enrollment 
(see total E. coli UTI by week, Figure 5).
Discussion
This study conﬁ  rms the presence of drug-resistant, 
genetically related, and, in some cases, temporally clus-
tered E. coli clonal groups (CgH, CgI, CgC, and CgA) that 
caused community-acquired UTIs in unrelated women 
in 2 locations and at different times. Drug resistance did 
not differ considerably between the 2 study sites, nor did 
the overall percentage of UTI caused by clonal groups: 
4% (95% CI 0.10–0.18) in Montréal and 16% (95% CI 
0.13–0.20) in California. Two clonal groups (CgA and 
CgC) were identiﬁ  ed in both study locations, indicating 
widespread dissemination. These clonal groups shared 
common serogroups, PFGE patterns, drug-susceptibility 
proﬁ  les, MLST patterns, and phylogenetic groups. CgA 
isolates identiﬁ  ed in Montréal did not show the same de-
gree of genetic homogeneity as CgA isolates identiﬁ  ed in 
the original California studies (11,14). CgA has also been 
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Figure 4. XbaI and NotI pulsed-ﬁ  eld gel electrophoresis patterns for 
clonal group A Escherichia coli isolated from women with urinary 
tract infections in Montréal, Québec, Canada, 2006 (lanes 434 and 
498) and Berkeley, California, USA, 1999–2001 (lanes 500, S203, 
W552, and S484). Antimicrobial drug resistance phenotypes and 
serogroups (O11, O17, O77, and O73) varied within and between 
the 2 study locations. First and last lanes, bacteriophage λ; lane +, 
positive control. 
Figure 3. XbaI and NotI pulsed-ﬁ  eld gel electrophoresis patterns for 
clonal group C Escherichia coli isolated from women with urinary 
tract infections in Montréal, Québec, Canada, 2006 (lanes 304, 
439, 362, 363, and 414) and Berkeley, California, USA, 1999–2001 
(lanes 410, 316, 458, 1688, and 1996). The 10 isolates shown 
were susceptible to all antimicrobial drugs tested and included 
serogroups O1, O2, or O18. First and last lanes, bacteriophage λ; 
lane +, positive control. UTI-causing Escherichia coli
recognized in many other locations and may represent a 
lineage that has been spreading over a longer period than 
other more genetically homogenous clonal groups identi-
ﬁ  ed (6,11,14,29). CgC members isolated from both study 
locations showed similar PFGE patterns, as well as com-
mon serotypes, MLST patterns, and phylogenetic groups, 
which suggest that these isolates are likely related. The 
fully susceptible nature of the CgC group and the similar 
drug resistance levels at the 2 study sites suggest that drug 
resistance or pressure may not have contributed to its se-
lection and dissemination.
Of the 4 clonal groups, 3 showed resistance to >1 an-
timicrobial drugs. Most worrisome was CgI, which was re-
sistant to ciproﬂ  oxacin and TMP-SMZ, drugs commonly 
used to treat patients with UTIs. Two members of CgI were 
resistant to 5 drugs. Identiﬁ  cation of CgI serotype O25:H4 
is also important because this serogroup and its drug re-
sistance proﬁ  le have been identiﬁ  ed in a recent report on 
an emerging CTX-M type ESBL-producing E. coli (sero-
type O25:H4 and ST131) found worldwide (30). A possible 
link between the O25:H4 E. coli clonal group identiﬁ  ed in 
Montréal and this emerging ESBL-producing E. coli clonal 
group should be investigated.
Temporal clustering (Figure 5) of these clonal groups 
from the 2 study sites was observed. Clonal groups tended 
to be identiﬁ  ed in women on the same day and week or 
in adjacent weeks; CgH in Montréal and CgA in Califor-
nia followed this pattern. However, many of the clusters 
caused by these clonal groups did occur sporadically across 
the entire study period. The observed correlation between 
increased incidence of total E. coli UTIs and increased in-
cidence of clonal group–associated UTIs may be a function 
of having sufﬁ  cient numbers of UTIs to be able to detect 
these clonal groups of E. coli. However, underlying ﬂ  uctu-
ations in community-wide dynamics of these E. coli clonal 
groups (in a human or environmental reservoir) may inﬂ  u-
ence the overall number of clinical infections.
One strength of our study is the ability to directly es-
timate the proportion of UTIs caused by each clonal group 
in the study communities. Because the study included all 
consecutive UTI specimens from a deﬁ  ned population and 
all E. coli were cultured and analyzed, it was possible to 
produce unbiased estimates of these proportions. Labora-
tory-based studies may overestimate prevalence of drug 
resistance, which in turn may bias the estimated proportion 
of clonal groups detected when specimens from recurrent, 
relapse, or complicated UTIs are disproportionately repre-
sented in the study samples. 
One limitation of our study is the lack of epidemiolog-
ic data on possible E. coli transmission routes. Lack of epi-
demiologic information makes it impossible to determine 
what speciﬁ  c risk factors led groups of women to become 
infected with indistinguishable strains of E. coli. Therefore, 
detection of a speciﬁ  c transmission route (e.g., foodborne) 
could not be directly addressed in this study. However, an 
earlier study, on the basis of epidemiologic data, has im-
plicated frequent consumption of chicken and pork in the 
development of drug-resistant UTIs (31). Also, limited re-
producibility of the ERIC2 PCR may have contributed to 
an underestimation of the number of clonal groups, par-
ticularly those clonal groups with only a few members (32). 
However, additional genotypic and phenotypic analyses 
applied to these isolates contributed to the valid classiﬁ  ca-
tion of these clonal groups.
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Figure 5. Temporal patterns of cases of urinary tract infections (UTIs) with Escherichia coli clonal groups by week in Montréal, Québec, 
Canada, 2006 (A), and Berkeley, California, USA, 1999–2001 (B). Clonal groups are identiﬁ  ed by letters in boxes. Lines indicate the total 
number of UTIs with E. coli in each week for each study site. Samples were not analyzed during February–October 2000 in Berkeley.RESEARCH
Genetic homogeneity of the clonal groups identiﬁ  ed in 
this study (CgH, CgC, and CgI), in addition to similar ob-
servations from other reports (6,10,17), suggests that these 
clonal groups are circulating in humans, most probably as 
part of the intestinal reservoir, and that they contribute to 
a sizable fraction of UTIs in the community. However, the 
degree of relatedness within each clonal group varied. For 
example, certain clonal groups (notably CgH) were highly 
clustered in time and showed indistinguishable genetic and 
other characteristics, which suggests local and recent trans-
mission. Other clonal groups showed more diversity (e.g., 
CgA), possibly reﬂ  ecting long-term, endemic transmission. 
These results suggest 3 competing or coincident ques-
tions. First, do local, punctuated epidemics of speciﬁ  c strains 
or clonal groups occur as observed in this and earlier studies 
(6,10,33)? Second, do these clonal groups belong to a set 
of fairly conserved endemic clonal groups that are adapted 
for persistent and predominant colonization of the intestinal 
tract, and which have spread widely in human communities 
over varying periods of time (6,10–14,29,33,34)? Third, a 
combination of the ﬁ  rst and second questions, are there pe-
riodic (epidemic) introductions of E. coli clonal groups in 
a community by an external source followed by endemic 
transmission? Already some evidence has indicated that 
animal-based foods or retail meats may contribute to the 
spread of these clonal groups (19–21). The number of infec-
tions, timing, and diverse locations in which these clonal 
groups are found argues against the possibility that person-
to-person or household transmission contributes to our ﬁ  nd-
ings. However, limited local spread by these routes by cer-
tain clonal groups cannot be ruled out (35–38).
Positive and negative implications are associated with 
our results. One positive implication is that identiﬁ  cation 
of lineages or clonal groups of E. coli that cause a size-
able fraction of community-acquired UTIs or extraintesti-
nal infections may contribute to rational development of 
therapies and prevention strategies targeted toward these 
lineages. One negative implication is that tracing transmis-
sion routes and understanding the dynamics of these E. coli 
in external reservoirs and in human populations will be dif-
ﬁ  cult and may impede possible control efforts, although 
ongoing attempts are under way to screen retail meats as a 
potential reservoir.
Annual incidence of UTIs and other community-ac-
quired extraintestinal infections is high, in the millions, 
worldwide. Although each clonal group may account for 
a small fraction of all UTIs in a community, the high inci-
dence of these infections implies that these clonal groups 
may contribute substantially to the overall extent of ex-
traintestinal infections caused by E. coli. Furthermore, 
these clonal groups contribute, not only to uncomplicated 
infections such as cystitis, but also to severe infections such 
as pyelonephritis and septicemia (13,39,40). At a mini-
mum, 10%–20% of these infections may be caused by 1 
of a small set of extraintestinal pathogenic E. coli clonal 
groups, which are commonly resistant to >1 drugs. These 
facts point to the public health importance of understanding 
these E. coli lineages and their dynamics in the community 
and possible environmental reservoirs.
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